Growing community of inventors

Cleveland, OH, United States of America

Kaustav Bera

Average Co-Inventor Count = 3.59

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Kaustav BeraAnant Madabhushi (7 patents)Kaustav BeraPranjal Vaidya (6 patents)Kaustav BeraVamsidhar Velcheti (3 patents)Kaustav BeraAndrew Janowczyk (1 patent)Kaustav BeraPrateek Prasanna (1 patent)Kaustav BeraPatrick Leo (1 patent)Kaustav BeraKaustav Bera (7 patents)Anant MadabhushiAnant Madabhushi (106 patents)Pranjal VaidyaPranjal Vaidya (7 patents)Vamsidhar VelchetiVamsidhar Velcheti (16 patents)Andrew JanowczykAndrew Janowczyk (10 patents)Prateek PrasannaPrateek Prasanna (8 patents)Patrick LeoPatrick Leo (3 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Case Western Reserve University (7 from 1,306 patents)

2. The Cleveland Clinic Foundation (2 from 1,036 patents)


7 patents:

1. 11676703 - Combination of radiomic and pathomic features in the prediction of prognoses for tumors

2. 11610304 - Predicting tumor prognoses based on a combination of radiomic and clinico-pathological features

3. 11574404 - Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC)

4. 11494900 - Prognosis of prostate cancer with computerized histomorphometric features of tumor morphology from routine hematoxylin and eosin slides

5. 11464473 - Distinguishing minimally invasive carcinoma and adenocarcinoma in situ from invasive adenocarcinoma with intratumoral and peri-tumoral textural features

6. 11350901 - Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography

7. 10839513 - Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/9/2025
Loading…